Julien Guiraud is a PhD student in the department of psychiatry at the University of Amsterdam, under the supervision of Pr Wim van den Brink. He has a Master of Science degree in aerospace engineering of ISAE-SUPAERO and a Specialized Master degree of HEC Paris. His doctoral program examines the efficacy and the safety of sodium oxybate in the treatment of alcohol use disorders.
Julien Guiraud was Chief Executive Officer of D&A Pharma, a company specialized in the development of pharmacotherapies for the treatment of various addictions, from 2014 to 2021. He is now the founder and President of Vergio, a company which provides services in clinical development.